ESTA - Earnings call transcript Q1 2024 | Establishment Labs Holdings Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, today's call is being recorded.

I will now turn the call over to Raj Denhoy, Chief Financial Officer. Please go ahead.

Rajbir Denhoy

Thank you, operator, and thank you, everyone, for joining us. Juan our is Executive today me Chacon Chief Quiros, Officer. With

your prepared remarks, our questions. we'll Following take

and Before management's we will development for would laws. outlook by statements within begin, and I forward-looking meaning and These management current comments you the uncertainties. based involve plans Establishment are during sales. made include that the statements risks These this Labs' federal company's and product call of include expectations on statements like forward-looking on securities to financial remind timing and

a of filings, Form that annual recent materially to or as XX-Q are results For discussion factors encourage which the and other on our and available most differ may cause establishmentlabs.com. and well principal as uncertainties website quarterly to from risk I our at performance these reports statements, affect on SEC our review XX-K actual Form

be not with which constant financial I'd or our performance, remind certain also like profitability which of our currency to non-GAAP but non-GAAP to, as may company's found available, measures, can press measures Reconciliations stated GAAP that on our include which on business, respect a to EBITDA. if be EBITDA may or for stated today's in limited comments be sales measures basis is to comparable available the release, adjusted you including, financial website. can results,

is for regulatory trial The date statement check undergoing of States. Labs clinical after over as no an May the our to turn your exemption obligation United content it or revise call are contains my of approved. events the from call. With seek the this a call live Establishment Motiva support as Jose. in any Except device availability. and to CEO, or authority to this of Labs information to the broadcast, with conference investigational time-sensitive in also otherwise expand note of undertakes day required pleasure by reflect that is receive law, Please to which our continually circumstances only local Establishment this accurate Please that, XXXX. FDA for regulatory products Juan update product We X, the Implants geographies the to approval

Juan Jose Quiros

Revenue $XX.X you, quarter afternoon, first everyone. and million. good XXXX totaled the of in Thank Raj,

to continue seeing markets stabilize, and Our demand. are improving we

global markets, this All of and continued our first sequential and XXXX. in regions direct throughout improvement showed to distributor expect We both the we improvement quarter. our in saw see

Our a Adjusted the million. second undertook first activities quarter $XX from quarter. loss showed loss and to a of we the cost efficiency notable results million last less EBITDA of improved of than in year. the improvement last also of the improvement was $X tangible reduction half This

a We in are start off busy XXXX. to

launched Over United implants in the past in Motiva several months, our expander States. China the tissue Flora we in

the our progress surpass States. is and of approval making on to This also to are our Motiva continues the implants the significant world offering expectations. clinics number We this United growing, in breast own of technology transformative me even feedback around

flow cash achieving positioned reach well margin in improving profitability scale our We multiyear are steadily necessary for structure while in the XXXX. growth to

Raj our Medical Motiva important of study. X by X our I we moment. on outlook study from at results provide investigator Caroline the to path principal is May data will want developments a the and our Dr. presented X-year several week, The Director announced Aesthetic events. more on financial approval. to in on Last the Meeting U.S. IDE recent a was But Glicksman, highlight U.S. first,

X our Baker is notable particularly not it years. for Grade changed IV As have III that Dr. highlighted, rates and contracture and past capsular Glicksman of rupture the

complication products and contracture be adopt surgeons we their the only years a implants, rupture, our These at patient exact same at confirmation with plastic breast which patients At standard a for and low and X will X superiority capsular numbers new year performance. were suspected given X of are X, only with expect technological rates X to there years. continues a and

these X the the the competitors X In from X Grade noting U.S. data at XXX comparative showed capsular that years, While IV it X study, it in women largest studies, developed that FDA X is Motiva are in or worth X between III XX the a in women. Baker and in not contracture. was

the also imagine plastic lead Allergan strong commercial market. U.S. and Motiva to of for XX anyone last experience Breast this over suited our better the division business. of leader most recently announced will that Jeff North Ehrhardt Aesthetics industry. was and is portfolio. week with We responsible American Jeff years to the in a reconstruction Products cannot Jeff ran I introduce

outreach Jeff This is is team. record [ surgeon this to with our a of who lead truly building will U.S. Pugh, industry, and will our in is successful Anne community. including already plastic experienced Business and team; team Ben Engagement Development, ], Director an the an who head track all-star Newcott Surgeon sales

of confidence have the At in predict for to of and Plastic and United line quarter the to second the decades. Society aesthetic FDA and our conference. know facilities exact an on in the XXXX. conversations we Motiva will new That we product said, an with our Motiva regulatory the of continue be United market launch surgeons States. critical process, And in highly this the Motiva available inspection not want The States past competitor anticipated most both launch and of talk high the Labs while were Establishment that overwhelmingly constructive, time a the the in are Meeting Annual and alike we the is will reasons. Surgeons be point are hires investors when will in might Vancouver be of in Aesthetic about the weekend, enthusiastic

as port the This come in labeled booth of to advantage Flora the as MR as and throughout we will distinct FDA. Vancouver to Motiva technology include continues had is reconstruction, has in about market. available well surface conditional our our Flora, RFID-enabled traction continue While XXXX. including by patented SmoothSilk we nonmagnetic this wait novel of Flora tissue many to commercially the the as course unique for gain adoption Flora approval learn U.S. breast of an our expander, important features, all expanders other tissue technology by in is many the and expect advantages magnets. We a of surgeons and

and We have of in a the VAC at centers are United number completed premier pending. the more process the cancer States

reconstruction the hospitals community, U.S. providing As in demonstrated grow breast are shared and patients number to clinical in device the of this the will of being the benefits in Flora

new the of Jose. Mia of Latin cities Mia San in list across available experience X Femtech Femtech up In new to signed invasive entirely and QX, creating Riyadh, Mia geographies, clinics world continues centers XX being hometown in where of an in education for now which the the partnership, XX of we aesthetics minimally Mia Abu practice is within medical onboarded process have clinics We grow. Jeddah, have added for provide Middle in are XX Dubai, Beirut is and In and America. total, certified Dhabi, category in our to East Mia new operating development. centers breast the we

have XX under negotiation. clinics we addition, In

Mia, media, growth harmonization driver confirming creating social that Mia Femtech. highlighting will consumers we breath but experiences conviction journey, on for It our launch word outcomes of this the sharing that the is are in we proof capturing demand their in mouth new ultimately the in early Mia and of the seeing new biggest breast are are points and category aesthetics. still aesthetic of convenience be consumer

Motiva launch offerings as has innovation, our have of recent China, and market. surgeons pay is been reception and a latest In such the willingness to the this in consumers and Chinese appreciation plastic for in strong science premium for technology strong. a there a

us partner position leaders. aggressive events pursuing China next over confidence cities where have X surrounding The in education and we early strategy years seen China. we Our market match and is results Tier distribution an that our market exclusive markets will what the medical in across Asia, are in in few Tier X of marketing give

I to turn will over call Raj. the now

Rajbir Denhoy

first were $XX.X XX% distributors up Thank a implant was sales quarter for year first perspective, Direct Middle Total decline the the Europe, America, approximately largest and global quarterly period. globally, sales, million, of accounted while you, Jose. ago made in market the from East XX% balance. Asia approximately quarter Latin Juan the the of were total Africa sales. is XX% XX%; From of Pacific, approximately a for in of and total, sales XX% XX%; our regional Brazil, which revenue

to of compared the quarter XX.X% revenue, for the XX.X% revenue in same or $XX.X profit period $XX.X of gross Our million million was XXXX. or first for

colón Rican the U.S. headwind. continued rates Changes profit an in quarter prices higher dollar in overhead first selling offset by exchange Our average year-over-year, increase the in be to between reflected the and and labor Costa costs. somewhat foreign a gross also

of dollars, in operating the report colón has strengthening we the As U.S. in resulted higher continued costs.

declined compared declined $X to fourth approximately million SG&A expenses $XX.X in quarter. of million million expenses also for $X.X first the the in million SG&A the to from first million approximately the XXXX. quarter reported $XX.X $XX.X quarter

the quarter million million a to quarter million same R&D $X.X year sequentially. expenses first the $X.X for $X.X approximately declined ago and from down were

XXXX initiatives was the in $X $XX.X million cost were initiatives. primarily in the of we the period decrease fourth reduction million of second the the decrease as year. expenses to year of $X.X and of quarter first first and approximately this declined into operating quarter approximately the reduction expenses planned XXXX expenses certain in operating for the in a due million, as well the timing The result half primarily Total quarter from undertook ago cost

compared fourth Net XXXX same million in loss in million, loss $XX.X from quarter. to period of operations was net for million the quarter $X.X and a first the $X.X in the

loss a a of million compared EBITDA period. the the of quarter and loss $X loss quarter. million This $X.X in in million Adjusted in to of was $XX.X year the fourth ago a

cash the million, Our to XXXX. XX compared million $XX on of $XX end was March position at

was million Excluding from our used proceeds first placement, the $XX January quarter in cash $XX.X underlying private million. the

We As $XX tranches million on the U.S. sales. on the $XX a $XXX X debt in approval achieving access the Motiva second and reminder, with milestone million trailing of totaled we which million. can implants facility, our have XX-month additional of FDA first remaining

revenue implants States. XXXX, to the continues Motiva exclude guidance For our contribution the in of United

to XX%. to remains growth at representing guidance of million, X% million $XXX $XXX Our

We expect a on to results year. impact have currency this our minimal sales

higher points margins of basis XX.X% approximately than gross XXXX to be XXXX expect to continue XXX XX%. range We a to to in

year pacing given implants going U.S. The this expenses in to approval of of of the Motiva fluid be is the operating timing

us in approval led confidence to this limited begin launch. prepare activities increasing hires the begin for has Our some key making year to to and

we such, expenses will operating from expect first quarter levels. increase As modestly

of investments the end by use. EBITDA and U.S. positive by focused commercialization managing in remain achieve cash adjusted these the U.S., operating when and timing the effect of on XXXX. We flow targets. cash we will And expenses end we're of XXXX The targeting excluding positive

the the strong will to States, current launch very capital, given plans. which business support ASPs our quickly. profitability America available fully United additional our in achieved North However, becomes us more the than Also

very credit facility cash our the and are we for accessible to on need or without properly capital. business which on is We profitability under the ensuring hand focused our additional currently us that have fund

I turn call Jose. will back Juan to now the

Juan Jose Quiros

Raj. is to Thank you, XXXX off a good start. very

recovery refocusing invest profitability. our steady restructuring us differentiated organization year technologies seeing the progress and we to and end we did work in are The support continue growth, progress our allowing of towards our markets to last while at is globally. in We in

investments flow of for by an management team. positive Our EBITDA intact cash us the and and adjusted U.S. a as in of the remain key are the excluding focus positive being goals next firmly organization year, end and year

second standard Early while is this year, establishing Flora reconstruction globally. us technologies the we new for of market largest pushing entered deeper care. China, into a breast our

in JOY supporting Femtech, Our which program Mia implants expansion and an over will time. to ergonomics, offerings most is course, breast family creating recent new real of entirely category market which and lead like of too, aesthetics exciting new

to be at of women The rest and work in Establishment cannot market United culmination world. launch and surgeons of our of years introduce largest in year is exciting. pending wait the the Labs, the to more Motiva even States a will story we of the The in

leader on company focused breast a the we as a on in are to reconstruction. and globally establish have a As clear and solid women's health, building aesthetics path foundation further ourselves

your now will operator call for I the over the turn to questions.

Operator

Harrison from Stephens first with Inc. Our Instructions] question [Operator is Parsons

Harrison Parsons

release spoke with This and on know in reiterated kind a demand start your to stabilizing. guidance. dig wanted your to George. from I you, macro in of underlying press market is on what just wanted in guidance. Harrison I you're assumptions perspective the assuming that for to I

Rajbir Denhoy

see markets over improvement of in as come to we better. second seeing we Generally, quarter, fourth in where quarter, similar demand. saw direct nice quarter. level a The a we you improvement doing saw into Sure. are as expect Harrison, we this we're were sequential move a orders in And back. the bit distributor the

And so stabilizing. things are generally,

And the expect we so through we is progress going that continue. Yes. year, to as trend

are So things and overall, where about we there. and better definitely out are feel how getting things we shaping pretty up good are

Harrison Parsons

you but for that know, for that's throughout but wanted be on a you're your going to Yes. remainder? the And those And I what know bit to a going obviously, touched levels Great. from their headwind little then on I the you think do inventory dig Where I the in expectations control, hearing are inventory today? your distributors? international of is it, out your or just tailwind what sit a year? levels

Juan Jose Quiros

demand our all around partners world. from and hear is of distribution that improving, much the we What regions the that's is very world Yes. in

I to as their expect as regions. as the probably a and lagger ordering in that's don't they're inventories, they're a demand back We And why course, other come is America there. think running Latin through again. result, quickly of there

distribution pattern normalized more to like it demand at levels around we saw the the XX-XX you was of consider quarter, back If what this percentage.

Operator

from Allen question next is Our with Gong JPMorgan.

K. Gong

So want kind into about dive getting seems how just trends talked it markets, direct to right? I deeper You like better. are of

kind of bit guidance So relative assumptions you get think the that, reiterated a we end when quarter the higher we of you better. range? or think fact Street about How that least that the bottom that of a expectations looks about should to the little to at off

Rajbir Denhoy

Yes.

second things Allen, sequential quarter. we about quarter talking improvement can sequential we're right? year, in the feeling through X really this question, are into And the You think, improvement commented I right? better, only similar see we're quarter. in the trends, the a the it as to What last

so So But that this the in to we feeling early upper end of year. adjusting the about in good at of it's terms be trending really range, the and that. year, this we're where point pretty are we feel overall, towards range

K. Gong

it. Got the know a kind talk year, you I of then of anticipation U.S. U.S. later health guess I just still to we're this underlying can And of launch the in bit was and waiting kind the of societies from pandemic. it to volume quite around XXXX, for out the but put in that bouncing data the really of the a we saw during wake market?

So can and the talk the how health to U.S. underlying that you of year? a you the for back positions just in launch half of the

Juan Jose Quiros

Thanks, Yes. Allen.

Surgery what just they the normalize taking dip they from we pandemic, close saw Plastic last we were where starting really that And hype at down they said And meeting it this to Vancouver. level had from all what the So the to of we the place. a the according the second U.S. like surgeons opportunity significant I normal many not demand procedures States. did But over plastic in part all over is nearly year. of Society the And think over see with about they is of American have Aesthetic they in United improvement talk an week. course, to that to the heard them saw during last is, of It above see

Operator

next from with Marie BTIG. Our Thibault question is

Marie Thibault

how we hoping to bit this on to thinking sales love U.S. force a Congrats place, the you're to would detail with I range wait how to start would in nice But wanted about and more I the bigger the can that know ask year, with here approval little a that hear love I really some about you're the to a build-out expected year. sales Jeff just very about get going strategy the targeting? I see have selling hear for bit strategy. and many be on reps a to spending to we'll little potential investment. of go-to-market

Juan Jose Quiros

Well, some Marie. have U.S. quite we for the been in Yes, investing time.

And office and a areas we been the built finance have infrastructure HR, commercial We our have back in regulatory leveraging legal, lot necessary from ops. we team. of like global especially commercial organization, foundation for building the the are also the

done and consider why U.S. what of So we've already the we that's and expanders already Flora we're invoicing been to tissue shipping part

to think not and did Ben that, are with Now that the Newcott, will head and we to who's U.S. experience I Development. in would say, on And none. we having strong launch. Jeff we the I we our for Anne what Jeff, second it market is building basically only readiness. Director Business of is, need Surgeon with who Their team And board, for get Engagement launch combined foundation the conviction our U.S. Pugh, preparated sales U.S. also signals add add

are we sales to of how our be We going very force. mindful grow

we're that the as the we've already there. continue the closer point tissue But commercial months to already and reps to we closer expander, to next more for a And foundation that added add couple launch. foundation, think getting the sales getting we that are where I we and like in of few feel is

of to point For too force. that definitely, to the up competitive building a we but start details, going are going I'm reasons, much at not sales share we are where

Marie Thibault

going That's on great should can revenue Any my how recognized here market And China see offer I amount to sort China. to to share details question year? you expectations? hear. or that we where think ability over on eventually quarter to this Okay. going wanted in the China? then of of about next the to more according Is ask in it And

Rajbir Denhoy

I little expected. that. we and It we've to developing about tracking what China, that tell can XXXX, building. -- start can we we we expected share. as talk China about I the we We XXXX. as a had right, is is in with JJ through as market demand. seeing pushed Yes. move talked are We're that, can think into I you 'XX,

we're plans track terms can that on And tell you of in in so I China. our

you eventual share terms In JJ, to market, take of of and the size market that? want that if maybe

Juan Jose Quiros

course. of Yes,

So months been in since It's and we launched basically Tier this X it's super point, education. a few cities at events, where, just with medical our early hitting Tier on. China, X

There's a Chinese quickly to experience a pay. it's other Singapore, Kong. they that surrounding a have very you like is in a good in that willingness technology. So we But this in countries we And in Taiwan, what early. have Hong strong blueprint countries have is where Asia, that we superior the see realize population used

So we leadership and some years seen In that the same XX% we China, share. XX% one few more or the market share. the have next countries share between we've do in now, to in of match expect our surrounding XX% where market right of competitors our has market

very a to detail as about build able have clear this we'll on to we how about launch go So activities, think plan And be how we there. on doing with initial definitely, that. talk are more we I

Operator

Our Anthony next from Securities. with is question Mizuho Petrone

Anthony Petrone

process the the and the what Maybe inspection FDA time long of range of one, that on just actually and turnaround takes how is.

process get follow-up of So package just potential that timing idea the care catalyst year. March. that on on was then be this the And just stimulus specifically, trying to some a see companies consumer-related out. and the There are plays health there a as the would question do actual half an China second into of how other announced in

China actually lead think stimulus the you could half? as to upside we get do into second So

Juan Jose Quiros

you, thank Anthony. Well, Yes.

for we it. of And able and can first approval looking openly talked time prepared What our tell for In and now Rica making Costa one, a significant us last about been that manufacturing inspection is the had QX. are good than the is have scheduled to the the our FDA to were approval post-market in and we approval. last I with you facility XX date team given that On the about days. progress in studies, labeling take we steps it. less well these forward before super FDA parallel, is speak place

on So that mindful want we process. disrupting us final to this, not be are stages we very of getting very and

can package, well good really through, very that a think And take to it we're and in It it, it's the so time stimulus yes, will on aware China, development. we of the lowest happening breast in in But aesthetics of bouncing demand. XXXX. the it then, as And market consumer see been we do it's Chinese positive. impact a since Remember, back. actually get

levels us But will back Our was expectation to it maybe get able to be that XXXX. faster. there XXXX going that be to by stimulus package was

Operator

Our with next Taylor from Matt question Jefferies. is

Matthew Taylor

maybe that contribution was I'll is adding you're up gave. do that you in could that year? centers? Maybe percentage to to could the going wondering be this today? be you overall your about revenue see centers. is Femtech of I what encouraging And ask you on centers it's What I terms And frame mean for you're all maturity? one material how Mia these that signing Mia the think talk will at if then commentary you the

Juan Jose Quiros

those at what this of Yes, that terms in clinics, still And of to practice procedures point, that I clinics. the some year, have numbers that of so which what every in month. light that start see clinics, centers. the to think bringing provide in for to that started building September, in trying to all have create with the see I in tell Europe, we of of last I'd our are work qualitative of get new do we network that's entire things instance, the part But category at in single to new to we number one, of coming the you October like within marketing who would have them do Matt, really category. is We all to the started there. is level, one you where element, the assets, the a process those of per see of numbers can can

rush. not we're So a in

active right that the are -- that of of the signed point. getting this the cases However, that XX clinics I now of think last are year ones, that started course, have at course, XX already, of are in are having ones up those, who more fall

In addition, XX we have new negotiation. under clinics

clinics. cities, our And there every X that, getting of will one. couple that what in to of be city, by these will I you'll in are of be see end of think XXX a this expectations a We this Tier Tier some goal year. few have And clinics In is aspirational city, every X there after the those.

And we up. those is initial out the see XXXX, ramp understanding get this the can in we in mostly Mia. it qualitative, will you coming start at an getting But when you I but more clinics, of start of levels quickly and revenue start putting numbers to which think you seeing how

We But out dedicated It the qualitative to not I time revenue. becomes are very willing to part. Mia the when is it think yet be do first break that. material, ones to we will

Matthew Taylor

well stocking for Maybe It one yet? it China. million wanted out in spread the on guidance. going assumption? first follow-up And I and revenue just seems confirm to through any like kind was specifically, just are that year, you seeing your you half the of of is the that Is everything talked $XX the still there. just more about reordering

Rajbir Denhoy

We a It's still months of in now. been we've early just I mean, mentioned, as there January. one, couple launched as I

are as the we numbers starts to of tracking build year, the We'll the so back in is how half things it far, to described. So reordering see expected tracking. you but the

Operator

is Citibank. next with Joanne Wuensch Our from question

Joanne Wuensch

make consensus. commentary Very I nice I'm fourth did is are sure to want early up quarters how the that but quarters? the guidance the and on that next second, of quarter. third couple And I you you it the appropriately. just think about year, appreciate curious of in set sort the exceed

Rajbir Denhoy

Yes.

at $X quarter look in over you the first sequential mentioned, increase million. we about as Joanne, the quarter think, last I

it. second you the sequential again, quarter small have is the for to tends the year the the the be right dynamic a of in the the increase likely of the increase the think recovery year, but similar back as into It half unfolds, we'll sequential us quarters in third. see a of weakest way The think I markets. about to

And so well. see quarter growth third we'll into as the

this So in commentary distributor improving. the gets to made we're back about seeing it recovery markets, that the the orders generally,

a probably way good that's of it the balance to over think I think So about the year.

Joanne Wuensch

thinking States? of this in would anything there strategy the regarding I'm you of is then that the share sharing stage your comfortable could United go-to-market that at number process. your else anything pricing And need you you're salespeople or

Juan Jose Quiros

for give is Joanne, of out. cannot exactly it's Unfortunately, type Yes. the that reasons, this we competitive things

have understanding a States. the very clear We want price to how United of in we

will in coming SmoothSilk SmoothSilk market and X Motiva the products, our been the quarters products provide necessary best-selling make that after Round in the so And that launch, are years. different Motiva of investments necessary the move make sure accounts they into Those have to and the with Ergonomix. we we as are deserve. We we some the for international the many service

at all I tell you. So that's point, this can

Operator

TD question is final from Cowen. Jennings with Josh Our

Joshua Jennings

I your make team $X just on I that's And the mean team clinics was hoping had these Mia relatively I has in for some sanity our talked up Establishment check, sure first. still wanted -- dollar to generators partner per partner it follow that still Mia sounds that, play in Juan optimistic just you positive. past, Labs. that million to potentially? launch is rate to to Jose, account, million about your becoming like revenue early run get trends conservative is assumptions. clinic But per revenue are that

Juan Jose Quiros

couple you, will month. achievable. average numbers. Thank that million eventually that clinic direct Yes. number are to market, an a clinics to Labs. fall those lead We is is of that cases per is trend a for In XX the Like doing an starting last that recognized said, approximately think the Mia to $X began I by Josh. Establishment year,

now our of across cities, expand to for numbers that can So in achieved. network our conviction those gives what the job instance, And Europe. us be clinics to that's is a direct markets

kicked already distributor in. markets the of Some have

handle launch done, the the media that of has work social see a been East. can the in Middle in Mia across instance, several of Femtech, You cities lot to for

special. So that that building all you we are of tells something

growing on them Mia clinics something what low that market at not like is brings would in being or And current we unachievable. shiny what city the or market depending the Tier new think this And clinics And best. single to is see that Tier that we as breast when those you And object. digits get aesthetics, about there. X for is X first at what numbers are can the year, see is we second see

Joshua Jennings

appreciate on on on was Flora traction the regions? to can affairs you I internationally, of U.S. updates of I on the recon in provide state And just franchise Great. the side the implant side. the launch. other Europe expander just Any and of the and some hoping in color there on tissue both check

Juan Jose Quiros

plastic Yes. because one, breast said think lower that I On you're again, is that times what is we've reconstruction surgeon. just not convincing a Josh, many really

the and of convince place. a take then a plastic a wait hospital to surgeons have for to reconstructive in You tender department

why, the see we Flora who a adopted normally from implants on at the hospitals, that's still breast speed So when have market have into great to adoption and with that go see who we same started not use of feedback purely is we Flora going although or aesthetics.

and it health think of build, a big in our demonstration this and time, credentials over will our it's women's technology I However, industry.

Operator

remarks. the all Juan back I closing the Jose is That call to now today. for for time turn we will have over questions

Juan Jose Quiros

happiness. everyone today's Thank our you look and on we We joining in providing and for update good quarterly next continued call. us to health wish forward August,

Operator

today's concludes This conference. you. Thank

for You time, may you disconnect participation. your lines and this your at thank

Establishment Labs (ESTA) 8 May 242024 Q1 Earnings call transcript